The World Health Organization has initiated a new phase of its Solidarity clinical trial to assess three new drugs – artesunate, imatinib and infliximab – in hospitalised patients with Covid-19. These drugs, currently used to treat other diseases, are expected to lower mortality risk in Covid-19 patients. The new trial, Solidarity PLUS, will be conducted at more than 600 hospitals across 52 countries.

The European Medicines Agency has launched an investigation regarding a possible link between two mRNA Covid-19 vaccines and new suspected side-effects reported in a few recipients. The agency is assessing whether Pfizer-BioNTech’s Comirnaty and Moderna’s Spikevax vaccines can cause an allergic skin reaction called erythema multiforme or two kidney disorders – glomerulonephritis and nephrotic syndrome.

I-Mab has reported positive interim results from the Phase II/III clinical trial of its antibody candidate, plonmarlimab, to treat cytokine release syndrome (CRS) in severe Covid-19 patients. The drug was observed to increase mechanical ventilation free rate, decrease mortality rate and shorten time to recovery and hospitalisation period. It also mitigated pro-inflammatory cytokines and chemokines that are considered vital in CRS. Plonmarlimab was well tolerated during the trial, without any notable safety issues.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData